A joint research team from HKUMed and HKUST has demonstrated that ZCB11, a broadly neutralizing antibody derived from a local mRNA-vaccinee, shows pot...Read more

The replication and pathogenicity of SARS-CoV-2 Omicron BA.2 are comparable to that of BA.1 in experimental animal models. However, BA.2 has rapidly e...Read more

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.2 was a dominant circulating SARS-CoV-2 variant worldwide. Recent reports hint...Read more

The emergence of SARS-CoV-2 variants of concern and repeated outbreaks of coronavirus epidemics in the past two decades emphasize the need for next-ge...Read more

The Omicron (B.1.1.529) variant of SARS-CoV-2 emerged in November 2021 and is rapidly spreading among the human population1. Although recent reports r...Read more

The Coronavirus Disease 2019 (COVID-19) pandemic is unlikely to abate until sufficient herd immunity is built up by either natural infection or vaccin...Read more

SARS-CoV-2 leads to a global pandemic of COVID-19 with high infectivity and mortality1. Currently, therapeutic options targeting SARS-CoV-2 are very l...Read more

Background: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is believed to be mostly transm...Read more

SARS-CoV-2 is causing a pandemic of COVID-19, with high infectivity and significant mortality1. Currently, therapeutic options for COVID-19 are limite...Read more

Background: Coronavirus disease 2019 (COVID-19) is primarily an acute respiratory tract infection. Distinctively, a substantial proportion of COVID-19...Read more

Background: A physiological small animal model that resembles COVID-19 with low mortality is lacking. Methods: Molecular docking on the binding betwe...Read more

A research team led by Professor Hongzhe Sun from the University of Hong Kong has discovered that an orally administered bismuth drug, colloidal bismu...Read more

香港大學的研究團隊發現，白血病藥物他米巴羅汀（tamibarotene）經肺部給藥，能針對包括新冠病毒在內的多種病毒，提供有效的抗病毒活性。該團隊已經開發出一種可吸入的乾粉劑，可以將藥物傳送到肺部，從而增加肺部的藥物濃度，減少副作用的風險。該吸入器預計在兩至三年內進入臨床試驗。...

Background Clinical outcomes of the interaction between the co-circulating pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and s...Read more

Inhibitors of the proteasome have been extensively studied for their applications in the treatment of human diseases such as hematologic malignancies,...Read more

In this article the author name Kwok-Yung Yuen was incorrectly written as Kwok-Yong Yuen. The original article has been corrected....

202. Ye, Z.-W., Ong, C.P., Tang, K., Fan, Y., Yuen, K.-Y., Ling, G.S., Yuan, S., and Jin, D.-Y....

The in vivo pathogenicity, transmissibility, and fitness of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) varia...Read more

The Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the biggest public health c...Read more